Treatment of Graves' Ophthalmopathy with Oral or Intravenous Corticosteroids;Die Systemische Glukokortikoidtherapie in der Behandlung der Endokrinen Orbitopathie

Medizinische Klinik

Volumn 99, Issue 2, 2004, Pages 71-76

  Brauer, Volker F H ^a   Scholz, Gerhard H ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Akad Lehrkrankhs F S Univ Jena   (Germany)

Author keywords

Graves' ophthalmopathy; Oral and intravenous corticosteroids

Indexed keywords

CORTICOSTEROID; GLUCOCORTICOID; METHYLPREDNISOLONE; PREDNISOLONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CUSHINGOID SYNDROME; DISEASE SEVERITY; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; ENDOCRINE OPHTHALMOPATHY; FLUSHING; GRAVES DISEASE; HIRSUTISM; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MYALGIA; NEUROLOGIC DISEASE; OPTIMAL DRUG DOSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS; FEMALE; GLUCOCORTICOIDS; GRAVES DISEASE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; META-ANALYSIS; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS;

EID: 1242316988     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-004-1014-9     Document Type: Review

References (22)

1. Forster G, Kahaly G. [Endocrine orbitopathy 1998.] Med Klin 1998;93:365-73.
2. Kendler DL, Lippa J, Rootman J. The initial clinical characteristics of Graves' orbitopathy vary with age and sex. Arch Ophthalmol 1993;111:197-201.
3. Heufelder AE. Pathogenesis of ophthalmopathy in autoimmune thyroid disease. Rev Endocr Metab Disord 2000;1:87-95.
4. Sorisky A, Pardasani D, Gagnon A, et al. Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. J Clin Endocrinol Metab 1996;81:3429-31.
5. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000;21:168-99.
6. Bartalena L, Marcocci C, Pinchera A. Treating severe Graves' ophthalmopathy. Baillieres Clin Endocrinol Metab 1997;11:521-36.
7. Perros P, Kendall-Taylor P. Thyroid-associated ophthalmopathy: pathogenesis and clinical management. Baillieres Clin Endocrinol Metab 1995; 9:115-35.
8. Prummel MF, Mourits MP, Blank L, et al. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 1993; 342:949-54.
9. Nagayama Y, Izumi M, Kiriyama T, et al. Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone pulse therapy. Acta Endocrinol (Copenh) 1987;116:513-8.
10. Prummel MF, Bakker A, Wiersinga WM, et al. Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience. Eur J Endocrinol 2003;148:491-5.
11. Mourits MP, Prummel MF, Wiersinga WM, et al.oornneefL. Clinical Activity Score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1997;47:9-14.
12. Mori S, Yoshikawa N, Horimoto M, et al. Thyroid stimulating antibody in sera of Graves' ophthalmopathy patients as a possible marker for predicting the efficacy of methylprednisolone pulse therapy. Endocr J 1995;42:441-8.
13. Macchia PE, Bagattini M, Lupoli G, et al. High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy. J Endocrinol Invest 2001;24:152-8.
14. Werner SC. Modification of the classification of the eye changes of Graves' disease. Am J Ophthalmol 1977;83:725-7.
15. Association AT. Classification of eye changes of Graves' disease. Thyroid 1992;2:235-6.
16. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991;10:1665-77.
17. Kahaly G, Pitz S, Muller-Forell W, et al. Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy. Clin Exp Immunol 1996;106:197-202.
18. Kauppinen-Mäkelin R, Karma A, Leinonen E, et al. High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy. Acta Ophthalmol Scand 2002; 80:316-21.
19. Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous of oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 2001;86:3562-7.
20. Matejka G, Verges B, Vaillant G, et al. Intravenous methylprednisolone pulse therapy in the treatment of Graves' ophthalmopathy. Horm Metab Res 1998; 30:93-8.
21. Mourits MP, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 1989;73:639-44.
22. Krassas GE, Heufelder AE. Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts. Eur J Endocrinol 2001;144:311-8.